IMMUNEERING
Immuneering is a biopharmaceutical company with an emerging pipeline focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying its deep knowledge of translational bioinformatics to every stage of the drug development process. It has more than a decade of experience in translational bioinformatics and generating insights into drug mechanisms of action and patient treatment responses.
IMMUNEERING
Industry:
Biotechnology Medical Pharmaceutical
Founded:
2008-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.immuneering.com
Total Employee:
11+
Status:
Active
Contact:
+1 617 500 8080
Email Addresses:
[email protected]
Total Funding:
57.2 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API LetsEncrypt Apple Mobile Web Clips Icon WordPress Font Awesome Wordpress Plugins Mobile Non Scaleable Content Nginx
Similar Organizations
Advanced Cell Diagnostics
Advanced Cell Diagnostics is a molecular pathology company developing cell- and tissue-based diagnostic tests for personalized medicine.
AnaBios
AnaBios provides contract research services for biotechnology and pharmaceutical industries.
Cypris
Cypris is a market intelligence dashboard & patent search engine built for research and development & intellectual property teams.
GeneCentrix, Inc.
GeneCentrix is a big-data bioinformatics company developing software tools for early-stage drug discovery.
KalGene Pharmaceuticals
KalGene Pharmaceuticals is a biotech company that develops precision medicine therapeutics for patients suffering from Alzheimer's disease.
Aquestive Therapeutics
Aquestive is a specialty pharmaceutical company that advances and commercializes medicines to solve critical healthcare problems.
NMD Pharma
NMD Pharma is a small molecule drug discovery company that develops novel treatments of neuromuscular disorders.
NovAliX
NovAliX is a company that aids managers, scientists, and project managers with drug discovery projects.
PaxVax
PaxVax is a start-up developing candidate oral vaccines for key infectious diseases.
Protégé Biomedical
Protégé Biomedical is a company with a unique new line of hemostatic products developed to stop bleeding in animals and humans*.
Regor Therapeutics
Regor Therapeutics is an international biotech company that focuses in the therapeutic areas of oncology, metabolic and autoimmune diseases.
Sprout Pharmaceuticals
Sprout Pharmaceuticals is a medical company that develops products for the treatment of female sexual dysfunction.
Truwl
Truwl is a bioinformatics company that engages in accelerating and simplifying biological research.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Ion Pacific
Ion Pacific investment in Post-IPO Equity - Immuneering
Boxcar Capital Partners
Boxcar Capital Partners investment in Series A - Immuneering
Official Site Inspections
http://www.immuneering.com Semrush global rank: 5.14 M Semrush visits lastest month: 1.58 K
- Host name: 93.75.197.35.bc.googleusercontent.com
- IP address: 35.197.75.93
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
More informations about "Immuneering"
Immuneering - Crunchbase Company Profile & Funding
Immuneering is a biopharmaceutical company with an emerging pipeline focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying its deep knowledge of translational …See details»
Immuneering Corporation
Immuneering CorporationSee details»
Drug Development - Immuneering Corporation
More than nine million people die of cancer every year, demonstrating the urgent need to develop new medicines for patients in need. Yet traditional drug discovery is deeply inefficient. Drug …See details»
Pipeline - Immuneering Corporation
Immuneering’s novel drug candidates spare healthy normal cells by modulating cell signaling dynamics to selectively impact tumor cells. Oncology – Select Therapies. IMM-1-104.See details»
Immuneering Corporation - LinkedIn
Immuneering Corporation | 2,671 followers on LinkedIn. Better Medicines Through Signaling Dynamics | Immuneering is a biopharmaceutical company with an emerging pipeline focused on improving ...See details»
Investor Relations | Immuneering Corporation
Jun 5, 2024 The Company aims to achieve universal activity through Deep Cyclic Inhibition of the MAPK pathway, impacting cancer cells while sparing healthy cells. Immuneering’s lead …See details»
Immuneering Corporation (IMRX) - Yahoo Finance
Find the latest Immuneering Corporation (IMRX) stock quote, history, news and other vital information to help you with your stock trading and investing.See details»
Immuneering to Present at the Morgan Stanley Healthcare …
CAMBRIDGE, Mass., September 6, 2023 --Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with …See details»
Contact Us - Immuneering Corporation
[email protected]. Harold “E.B.” Brakewood. Locations: Boston. 245 Main St, 2nd Floor Cambridge, MA 02142. New York. 667 Madison Ave New York, NY 10065. ... we are a vibrant organization shaped by the challenges …See details»
Immuneering - Contacts, Employees, Board Members, Advisors
Organization. Immuneering . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. ... Immuneering has 3 current employee profiles, including Co-Founder and …See details»
Immuneering Reports Second Quarter 2021 Financial Results and …
CAMBRIDGE, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company advancing a robust pipeline of oncology and …See details»
Immuneering Appoints Biren Amin, M.B.A., as Chief Financial Officer
CAMBRIDGE, Mass., April 06, 2021 (GLOBE NEWSWIRE) -- Immuneering Corporation today announced the appointment of Biren Amin, M.B.A., as Chief Financial Officer. Mr. Amin comes …See details»
Immuneering Announces Closing of its Upsized Initial Public …
Aug 3, 2021 Immuneering’s lead product candidate, IMM-1-104, is designed to be a highly selective dual-MEK inhibitor that further disrupts KSR for the treatment of advanced solid …See details»
Meet The Team - Immuneering Corporation
Ms. Flannery joined Immuneering’s clinical team in October 2022. Prior to joining Immuneering, she held a variety of clinical positions in the pediatrics and dermatology fields before joining a …See details»
Immuneering Announces Pricing of Upsized Initial Public Offering
Jul 30, 2021 Immuneering’s lead product candidate, IMM-1-104, is designed to be a highly selective dual-MEK inhibitor that further disrupts KSR for the treatment of advanced solid …See details»
Immuneering Appoints Biren Amin, M.B.A., as Chief Financial Officer
Apr 6, 2021 Immuneering’s novel drug candidates spare healthy normal cells by modulating signaling dynamics to focus therapeutic impact against tumor cells. Immuneering’s platform …See details»
Immuneering Announces Participation in February Investor …
Feb 1, 2024 Immuneering’s lead product candidate, IMM-1-104, is an oral, once-daily deep cyclic inhibitor currently in a Phase 1/2a study in patients with advanced solid tumors …See details»
Immuneering Announces Positive Initial Phase 1 Pharmacokinetic …
Apr 18, 2023 About Immuneering Corporation Immuneering is a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to …See details»
Platform - Immuneering Corporation
Powering Drug Discovery and Development Through The Immuneering Platform. Platform. Our platform is enabled by our ability to efficiently analyze high-throughput molecular-level …See details»